Gary L Fox

US Patent:

6455277, Sep 24, 2002

Filed:

Apr 14, 1997

Appl. No.:

08/837199

Inventors:

Gary M. Fox - Newbury Park CA
Shuqian Jing - Thousand Oaks CA
Duanzhi Wen - Thousand Oaks CA

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C12N 1512

US Classification:

435 691, 435325, 4353201, 4352523, 536 235

Abstract:

The present invention relates to glial cell line-derived neurotophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. The present invention involves the cloning and characterization of a high affinity receptor for GDNF. This molecule has been named GDNF receptor (GDNFR) since it is the first known component of a receptor system. Nucleic acid and amino acid sequences are described for GDNFR protein products. A hydrophobic domain with the features of a signal peptide is found at the amino terminus, while a second hydrophobic domain at the carboxy terminus is involved in the linkage of the receptor to the cell membrane. The lack of a transmembrane domain and cytoplasmic region indicates that GDNFR requires one or more accessory molecules in order to mediate transmembrane signaling. GDNFR mRNA is widely distributed in both nervous system and non-neural tissues, consistent with the similar distribution found for GDNF.

US Patent:

6479250, Nov 12, 2002

Filed:

Jul 7, 2000

Appl. No.:

09/611452

Inventors:

Timothy D. Bartley - Thousand Oaks CA
William J. Boyle - Moorpark CA
Gary M. Fox - Newbury Park CA
Andrew A. Welcher - Glendale CA
Ella Magal - Thousand Oaks CA
Richard A. Lindberg - Thousand Oaks CA
Vann P. Parker - Newbury Park CA

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C12Q 148

US Classification:

435 15

Abstract:

Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.

US Patent:

6992175, Jan 31, 2006

Filed:

Aug 23, 1999

Appl. No.:

09/378759

Inventors:

Gary M. Fox - Newbury Park CA, US
Andrew A. Welcher - Glendale CA, US
Shuqian Jing - Thousand Oaks CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C12P 21/08
C12P 21/02
C07H 21/04
C07K 1/00
G01N 33/567

US Classification:

53038822, 530350, 435 695, 536 235, 514 2, 436501

Abstract:

Four novel members of the EPH sub-family of receptor protein tyrosine kinases are disclosed. Nucleic acid sequences encoding receptor proteins, recombinant plasmids and host cells for expression, and methods of producing and using such receptors are also disclosed.

US Patent:

7138251, Nov 21, 2006

Filed:

May 30, 1997

Appl. No.:

08/866354

Inventors:

Gary M. Fox - Newbury Park CA, US
Shuqian Jing - Thousand Oaks CA, US
Duanzhi Wen - Thousand Oaks CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C12N 15/12
C12N 15/63
C12N 15/70
C12N 15/85

US Classification:

435 691, 435325, 4352523, 4353201, 536 235

Abstract:

The present invention relates to glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. The present invention involves the cloning and characterization of receptors for GDNF. Nucleic acid and amino acid sequences are described for GDNFR protein products. A hydrophobic domain with the features of a signal peptide is found at the amino terminus, while a second hydrophobic domain at the carboxy terminus is involved in the linkage of the receptor to the cell membrane. The lack of a transmembrane domain and cytoplasmic region indicates that GDNFR requires one or more accessory molecules in order to mediate transmembrane signaling. GDNFR mRNA is widely distributed in both nervous system and non-neural tissues, consistent with the similar distribution found for GDNF.

US Patent:

7414122, Aug 19, 2008

Filed:

Nov 29, 2004

Appl. No.:

10/998526

Inventors:

Gary M. Fox - Newbury Park CA, US
John K Sullivan - Newbury Park CA, US
Paige Holst - Camarillo CA, US
Steven Kiyoshi Yoshinaga - Thousand Oaks CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07H 21/04
C12N 15/00
C12N 1/21
C12N 5/16
A61K 31/713

US Classification:

536 235, 4353201, 4352523, 435455, 435 691, 514 44

Abstract:

The present invention provides B7-Like (B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7-L polypeptides.

US Patent:

20020107363, Aug 8, 2002

Filed:

Sep 19, 2001

Appl. No.:

09/955866

Inventors:

Gary Fox - Newbury Park CA, US
John Sullivan - Newbury Park CA, US
Paige Holst - Camarillo CA, US
Steven Yoshinaga - Thousand Oaks CA, US

Assignee:

Amgen, Inc.

International Classification:

C12P021/02
C07K014/705
C12N005/06
C07H021/04

US Classification:

530/350000, 536/023500, 435/069100, 435/325000, 435/320100

Abstract:

The present invention provides B7-Like (B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7-L polypeptides.

US Patent:

20020165347, Nov 7, 2002

Filed:

Jun 29, 2001

Appl. No.:

09/896738

Inventors:

Gary Fox - Newbury Park CA, US
John Sullivan - Newbury Park CA, US
Mei Fang - Thousand Oaks CA, US

Assignee:

Amgen, Inc.

International Classification:

C12P021/02
C07H021/04
C07K014/435
C12N005/06

US Classification:

530/350000, 536/023200, 435/325000, 435/069100, 435/320100

Abstract:

The present invention provides B7-Like (B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7-L polypeptides.

US Patent:

20030175876, Sep 18, 2003

Filed:

May 24, 2002

Appl. No.:

10/155693

Inventors:

Gary Fox - Newbury Park CA, US
Shuqian Jing - Thousand Oaks CA, US
Duanzhi Wen - Thousand Oaks CA, US

Assignee:

Amgen Inc.

International Classification:

C07K014/435
C07H021/04
C12P021/02
C12N005/06

US Classification:

435/069100, 435/320100, 435/325000, 530/350000, 536/023500

Abstract:

The present invention relates to glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. The present invention involves the cloning and characterization of a high affinity receptor for GDNF. This molecule has been named GDNF receptor (GDNFR) since it is the first known component of a receptor system. Nucleic acid and amino acid sequences are described for GDNFR protein products. A hydrophobic domain with the features of a signal peptide is found at the amino terminus, while a second hydrophobic domain at the carboxy terminus is involved in the linkage of the receptor to the cell membrane. The lack of a transmembrane domain and cytoplasmic region indicates that GDNFR requires one or more accessory molecules in order to mediate transmembrane signaling. GDNFR mRNA is widely distributed in both nervous system and non-neural tissues, consistent with the similar distribution found for GDNF.

Address:

315 Linden Ave, Hellertown, PA 18055

Phone:

610 838-9758

VIN:

2GTFK13Y771723841

Make:

GMC

Model:

SIERRA 1500

Year:

2007